Deleted in liver cancer 1 (DLC-1), as its name implied, was originally isolated as a potential tumor suppressor gene often deleted in hepatocellular carcinoma. Further studies have indicated that down-expression of DLC-1 either by genomic deletion or DNA methylation is associated with a variety of cancer types including lung, breast, prostate, kidney, colon, uterus, ovary, and stomach. Re-expression of DLC-1 in cancer cells regulates the structure of actin cytoskeleton and focal adhesions and significantly inhibits cell growth, supporting its role as a tumor suppressor. This tumor suppressive function relies on DLC-1's RhoGTPase activating protein (RhoGAP) activity and steroidogenic acute regulatory (StAR)-related lipid transfer (START) domain, as well as its focal adhesion localization, which is recruited by the Src Homology 2 (SH2) domains of tensins in a phosphotyrosine-independent fashion. Therefore, the expression and subcellular localization of DLC-1 could be a useful molecular marker for cancer prognosis, whereas DLC-1 and its downstream signaling molecules might be therapeutic targets for the treatment of cancer.
Introduction
Deleted in liver cancer 1 (DLC-1, also known as ARHGAP7 and STARD12 in human and p122RhoGAP in rat) was first isolated from rat brain as a phospholipase C␦1 (PLC␦1) binding protein (Homma & Emori, 1995) and then was independently cloned by subtractive hybridization as a gene homozygously deleted in a human hepatocellular carcinoma (Yuan et al., 1998) . Together with its gene locus at human chromosome 8p21, a region frequently deleted in liver cancer, DLC-1 is considered as a potential tumor suppressor. Evidence is now emerging to demonstrate that DLC-1 is a focal adhesion molecule that plays a role in preventing cell transformation in the liver as well as many other tissues.
Structure
DLC-1 was also named ARHGAP7 and STARD12 because it contains a RhoGTPase activating protein (RhoGAP) domain and a steroidogenic acute regulatory (StAR)-related lipid transfer (START) domain, respectively. In addition, a sterile alpha motif (SAM) domain is found near its N-terminus (Fig. 1) . SAM domains are known to interact with each other forming homodimers. In other cases, they may bind to other proteins, RNA, or DNA (Qiao & Bowie, 2005) . However, the A focal adhesion targeting (FAT) region in the N-terminal half and a binding site for the SH2 domains of tensin family have been identified in DLC-1. The SAM domain is not required for DLC-1's function in suppressing cell growth or actin fiber and focal adhesion formation. The C-terminal half of DLC-1 contains the RhoGAP and START domains and binds to PLC␦1. This C-terminal region is necessary but not sufficient for inhibiting tumor cell growth, actin fiber and focal adhesion formation. It also requires the FAT fragment for DLC-1's tumor suppression activity. Overall, human DLC-2 and DLC-3 amino acid sequences share 52.8 and 40.9% identities to that of DLC-1. The SAM, RhoGAP and START domains are highly conserved. The corresponding FAT regions in DLC-2 and DLC-3 show 38.8 and 21.3% identities, and the focal adhesion localization has been confirmed for DLC-2 but not DLC-3. function for DLC-1's SAM domain remains to be characterized. START domains are predicted to interact with lipids (Iyer, Aravind, & Koonin, 2001 ) and yet need to be confirmed for DLC-1's START domain. RhoGAP domains convert the active GTP-bound Rho proteins to the inactive GDP-bound state and negatively regulate Rho GTPases. The N-terminal region of DLC-1 contains a focal adhesion targeting (FAT) sequence that binds to the Src Homology 2 (SH2) domains of focal adhesion proteins, tensins, and is therefore recruited to these sites (Liao, Si, Devere White, & Lo, 2007) . This focal adhesion localization of DLC-1 appears to be critical for its tumor suppressive function. SH2 domains are binding motifs for phosphotyrosine. Surprisingly, the interaction between DLC-1 and tensin's SH2 domain is independent to tyrosine phosphorylation of DLC-1. This SH2-DLC-1 interaction was demonstrated by yeast-two-hybrid, co-immunoprecipitation, pull-down, peptide binding, and subcellular localization assays (Liao et al., 2007) . By mutagenesis approaches, critical residues including serine-440 and tyrosine-442 on DLC-1 as well as arginine residue at ␤B5 position of SH2 domains of tensins were identified (Liao et al., 2007) . However, the same region of DLC-1 was reported to interact with the phosphotyrosine binding (PTB), but not the SH2, domain of tensin2 (Yam, Ko, Chan, Jin, & Ng, 2006) . These contradictive results remain to be investigated.
The C-terminal half of DLC-1 interacts with PLC␦1 and enhances the phosphatidylinositol 4,5-bisphosphate (PIP2)-hydrolyzing activity of PLC␦1 (Homma & Emori, 1995) . This PLC␦-enhancing activity may contribute to the role of DLC-1 in regulating the actin stress fibers (see Section 4). The C-terminal region also targets to caveolae presuming by interacting with caveolin-1 through several potential binding sites on DLC-1 Yamaga et al., 2004) . However, the significance of caveolae localization of DLC-1 is not clear.
Expression and regulation
DLC-1 is expressed in many normal tissues including brain, heart, kidney, liver, lung, skin, spleen, and testis (Durkin, Yuan, Thorgeirsson, & Popescu, 2002) . As mentioned, human DLC-1 was identified as a candidate tumor suppressor and in agreement with this notion, its expression was lost or down-regulated in various cancers including liver, breast, lung, brain, stomach, colon and prostate cancers due to either genomic deletion or aberrant DNA methylation (Table 1) (Guan, Zhou, Soulitzis, Spandidos, & Popescu, 2006; Kim et al., 2003 Kim et al., , 2007  Yuan, Durkin, & Popescu, 2003a; Yuan et al., 2004 Yuan et al., , 1998 . These results also suggest that DLC-1 may function as a tumor suppressor in tissues other than liver. Interestingly, dietary flavone is able to restore the expression of DLC-1 in some cancer cell lines that are DLC-1-negative due to DNA hypermethylation , suggesting a potential preventive and therapeutic benefits of flavone in some DLC-1 related cancers.
Biological function
Studies have demonstrated that re-expression of DLC-1 in liver, breast, lung cancer cell lines inhibits cancer cell growth (Goodison et al., 2005; Wong et al., 2005; Yuan et al., 2004 Yuan et al., , 2003b Zhou, Thorgeirsson, & Popescu, 2004) , supporting its major role as a tumor suppressor. The suppressive function may attribute to several known regulatory activities of DLC-1 such as the regulation of actin cytoskeleton, focal adhesion formation, and cell shape (Sekimata, Kabuyama, Emori, & Homma, 1999) , as well as induction of apoptosis (Zhou et al., 2004) . Rat DLC-1 binds to PLC␦1 and enhances the hydrolysis of PIP2 (Homma & Emori, 1995; Sekimata et al., 1999) , which is known to modulate actin cytoskeleton in multiple ways (Yin & Janmey, 2003) . The hydrolysis of PIP2 leads to the generation of diacylglycerol and inositol 1,4,5-triphosphate (IP3) that activates protein kinase C and induces Ca 2+ release from internal stores, respectively. Both protein kinase C and Ca 2+ are regulators of actin cytoskeleton (Yin & Janmey, 2003) . In addition, many actin-regulating proteins such as profilin, cofilin, and gelsolin bind to PIP2 and the hydrolysis of PIP2 will result in the release of these proteins and, in turn, bind to G-actin or the ends of actin filaments and accelerate the disassembly of actin fibers (Yin & Janmey, 2003) . This PLC␦1-enhancing activity of DLC-1 may act synergistically with its RhoGAP activity in inducing the cytoskeletonal and morphological changes. Previous studies showed that the C-terminal half of DLC-1, which binds to PLC␦1 and contains the RhoGAP activity and START domain, is necessary for inhibiting tumor cell growth, actin fiber and focal adhesion formation (Fig. 1) (Sekimata et al., 1999; Yam et al., 2006) . However, this C-terminal region of DLC-1 alone is not sufficient for these functions . Indeed, recent studies have indicated that in addition to the RhoGAP activity and START domain, tensin-binding activity is essential for its growth suppression activity (Liao et al., 2007) . The significance of this tensin-binding activity is to target DLC-1 to focal adhesion sites. DLC-1 mutants disrupted the interaction with tensins are not able to localize to focal adhesions and lose their suppression activities (Liao et al., 2007) .
In addition to the tumor suppressor activity, one report has defined DLC-1 as a metastasis suppressor in breast cancer cells (Goodison et al., 2005) . In this study, the gene expression profiles of metastatic and non-metastatic sublines of the parental MDA-MB-435 breast cancer cell line were compared and DLC-1 was down-expressed in the metastatic subline. Restoration of DLC-1 in metastatic cell line leads to the inhibition of migration and invasion in cell culture assays and a significant reduction in metastases in nude mouse experiments (Goodison et al., 2005) .
DLC-1 may also be involved in insulin signaling. Insulin induces the phosphorylation on serine-322 of rat DLC-1 (serine-329 in human DLC-1) (Hers, Wherlock, Homma, Yagisawa, & Tavare, 2006) . It was suggested that insulin-stimulated serine-322 phosphorylation could be regulated by either the PI-3 kinase/AKT pathway or the MEK/ERK/ribosomal S6 kinase pathway depending on the cell types. Although the function of this serine phosphorylation is currently unknown, it does not regulate the focal adhesion localization of DLC-1 (Hers et al., 2006) .
The knockout mouse studies have indicated an essential role for DLC-1 in mouse embryonic development (Durkin et al., 2005) . Homozygous mutant embryos die before 10.5 days postcoitus with defects in the neural tube, brain, heart, and placenta (Durkin et al., 2005) . Fibroblasts isolated from DLC-1 mutant embryos contain disrupted actin filaments and fewer focal adhesions (Durkin et al., 2005) . The embryonic fibroblast study results confirmed the role of DLC-1 in regulating actin cytoskeleton and focal adhesion structures. However, the early lethality of DLC-1 null embryos limited further study on its role as a tumor suppressor. The tissue specific deletion of DLC-1 in mice will provide more information on its roles in various cancers and may provide good animal models for those relevant human cancers.
Two molecules with extensive homology to DLC-1 have been isolated (Fig. 1) . DLC-2 (STARD13) gene locates at human chromosome 13q12, while DLC-3 (STARD8, KIAA0189) gene is at human Xq13. Both contains the SAM, RhoGAP and START domains, although one of alternative spliced forms of DLC-3 does not contain the SAM domain (Durkin, Ullmannova, Guan, & Popescu, 2007) . Down-regulation of DLC-2 and DLC-3 were also reported in various human cancers and the colony formation assay showed that both DLC-2 and DLC-3 inhibited tumor cell growth Durkin et al., 2007; Leung et al., 2005) . In addition, others and we found the N-terminal half of DLC-2 localized to focal adhesions (Hers et al., 2006; Liao and Lo, unpublished data) . Other report showed that the START domain of DLC-2 targeted to mitochondria .
Possible medical and industrial applications
As a tumor suppressor, understanding DLC-1's functions and its signaling pathways are crucial for both prevention and treatment of DLC-1 related cancer. DLC-1 and its downstream signaling molecules can be useful biomarkers for prediction and diagnosis as well as targets for therapeutic interventions in cancer. Downregulation of DLC-1 expression either by genomic deletion or DNA methylation and DLC-1 protein mislocalization could be indicators for tumor progression. Being a target in the insulin pathway implies that DLC-1 may be involved in glucose uptake and its abnormal expression may lead to diseases such as diabetes. Both possibilities are not established and warrant further analyses. The multiple involvements of DLC-1 in a variety of tissues expand its potential medical applications. The tissue specific DLC-1 null mice may provide good models for various cancers and diseases. Once more detailed biological functions of DLC-1 and its signaling pathway are revealed, it is possible to develop drugs to restore or enhance DLC-1's function in diseased cells. 
